Condition
No Evidence of Disease State
Total Trials
1
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
Treatment Research
2 treatments under study, led by Regorafenib
Research Leaders
5 sponsors active, led by IRCCS Ospedale Policlinico San Martino
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 1 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Phase 2 (1)
Trial Status
Unknown1
Clinical Trials (1)
Research Network
Common Treatments
- Regorafenib1
- Durvalumab Injection For Intravenous Use 500 Mg Vial Solution For Infusion1
Active Sponsors
- IRCCS Ospedale Policlinico San Martino1
- Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente1
- Bayer1
- Ospedale Policlinico San Martino1
- Associazione Italiana per la Ricerca sul Cancro1
Top Investigators
OSPEDALE SAN MARTINO IRCCS
Related Conditions
- Stage Iv Colorectal Cancer Patients With No Evidence Of Disease Ned1
- Colorectal Cancer Stage Iv1